Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
The short answer is that sermorelin was FDA-approved, is not currently sold as an approved product, and reaches patients today through compounding pharmacies. That three-part answer confuses people, and the confusion gets exploited in both directions: by vendors who imply sermorelin is an approved drug, and by critics who imply it was pulled for safety reasons. Neither is accurate. I spent 12 years in pharma, and the actual history is worth knowing before you start.
Geref: The Approved Product
Sermorelin acetate was approved by the FDA in the 1990s under the brand name Geref, manufactured by Serono. It had two approved uses: as a diagnostic agent to test pituitary function, and as a treatment for growth hormone deficiency in children. It was a legitimate, approved prescription drug with a full new drug application behind it.
The drug itself is a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH), the signal the hypothalamus sends to the pituitary. A 1999 review in BioDrugs describes its mechanism, pharmacology, and safety profile from the pediatric trials, where the most common adverse events were injection-site reactions and transient facial flushing.[1]
Why It Was Discontinued
Geref was withdrawn from the market in 2008. The reason was commercial, not safety-related. Serono discontinued production, and the FDA subsequently listed sermorelin in the Orange Book’s discontinued drug product list with a determination that it was not withdrawn for reasons of safety or effectiveness.
That distinction matters. When the FDA pulls a drug for safety, it says so, and the drug cannot be compounded. When a manufacturer stops making a drug for business reasons, the active ingredient can remain available through compounding under certain conditions. Sermorelin falls in the second category.
I will be careful with one point: the exact regulatory pathway under which 503A pharmacies compound sermorelin today is less tidy than vendors claim. Sermorelin is no longer a component of an approved product and does not appear on the FDA’s finalized 503A bulk substance list. It is widely compounded, and FDA has not acted against it, but the status is best described as permitted in practice rather than codified. Any provider or pharmacy that tells you it is “FDA-approved” with no qualifier is wrong, and any that tells you it is illegal is also wrong.
What Compounded Sermorelin Is
Compounded sermorelin is sermorelin acetate prepared by a licensed 503A compounding pharmacy for an individual patient under a prescription. The active ingredient is sermorelin acetate, the drug substance Geref contained. The product is not the same as Geref: it has not gone through FDA review for that specific formulation, manufacturing site, or batch, and it carries the compounded disclaimer you see at the top of this article.
What you are relying on, in place of FDA product approval, is the pharmacy’s state licensure, its compliance with USP standards for sterile compounding, and the prescribing provider’s judgment. That is a meaningful set of safeguards. It is not the same as an approved drug, and we do not pretend otherwise.
Why the Distinction Matters to You
Three practical consequences follow from sermorelin’s status.
First, sourcing matters more than it would for an approved drug. A compounded product is only as good as the pharmacy that made it. Ask which pharmacy fills the prescription, whether it is licensed in your state, and whether it is a 503A facility. If a vendor will not tell you, that is your answer.
Second, “research peptide” sermorelin sold online without a prescription is a different thing entirely. Those products are labeled for laboratory use, are not made under pharmacy standards, and are not legal to sell for human use. The price difference reflects that.
Third, the evidence base you are relying on is mostly older research on GHRH analogs rather than modern large trials. A 1992 study in older men showed that twice-daily GHRH(1-29) raised growth hormone and IGF-1 back toward the levels of younger men.[2] That is real data, from a real NIH-funded trial. It is also a 14-day study in 10 men. Anyone promising you a transformation is extrapolating well beyond what the literature supports.
The Bottom Line
Sermorelin had FDA approval, lost its commercial product for business reasons, and continues as a compounded prescription medication. That makes it neither a fully approved drug nor an unregulated supplement. It occupies the middle ground that most peptide therapy occupies, and the right way to approach it is with a licensed provider, a licensed pharmacy, and realistic expectations.
To see how our program handles prescribing and pharmacy sourcing, visit our sermorelin therapy page.
References
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PubMed: 18031173
Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PubMed: 1379256
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized guidance.
JP Rius is the founder of Precision Telemed. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.
